+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

COVID-19 Vaccines - Global Strategic Business Report

  • PDF Icon

    Report

  • 762 Pages
  • October 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5353024
The global market for COVID-19 Vaccines, estimated at 6.4 Billion Doses in the year 2023, is projected to reach 4.2 Billion Doses by 2025. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Regional Analysis:

Discover growth trends in key regions, including the US, China, Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global COVID-19 Vaccines Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global COVID-19 Vaccines Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the global COVID-19 Vaccines market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 358 Featured):

  • AstraZeneca PLC
  • Aurobindo Pharma Ltd.
  • Amyris, Inc.
  • AnGes, Inc.
  • Altimmune, Inc.
  • Arcturus Therapeutics, Inc.
  • ADImmune Corporation
  • AdaptVac
  • AJ Vaccines
  • Batavia Biosciences BV
  • ARTES Biotechnology GmbH
  • Baylor College of Medicine
  • baseclick GmbH
  • Barcelona Supercomputing Center
  • Akston Biosciences Corporation

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
MARKET OVERVIEW
  • Global Economic Update
  • COVID-19 Vaccines - Global Key Competitors Percentage Market Share in 2024 (E)
  • AN OVERVIEW OF COVID-19 VACCINE ROLLOUT
  • THE VARIOUS COVID-19 VIRUS VARIANTS
  • mRNA: A NEW APPROACH TO MEDICINE
  • mRNA Vaccine Marks Dawn of New Era of Vaccines & Medical Therapies
  • RNA Technology: Benefits & Potential for Future Outbreaks
  • Key Challenges
  • Efforts to Target New Application Areas
MARKET DYNAMICS
  • Impact of Vaccine Passports on Reviving International Travel
  • Developments Regarding Digital Certificates
  • Expanding Demand for mRNA Vaccine Technologies: A Deep Dive
  • Vaccine Companies Stress on Booster Dose
  • Managing and Monitoring Vaccine Side Effects: Increasing Safety
  • Vaccine Alliances Ensure Supplies for All
  • Licensing and Partnership Deals Worldwide Propel Vaccine Production
GLOBAL MARKET PERSPECTIVE
  • EXHIBIT 1: Global Percentage of Individuals Vaccinated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific (India, Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America), Middle East and Africa Markets - Independent Analysis of Percentage of Individuals Vaccinated for 2020 through 2025
  • EXHIBIT 2: European Percentage of Individuals Vaccinated by Geographic Region - France, Germany, United Kingdom, Italy, Russia, Spain, and Rest of European Markets - Independent Analysis of Percentage of Individuals Vaccinated for 2020 through 2025
  • EXHIBIT 3: Global Number of Annual COVID-19 Vaccine Doses (In Million) for Years 2020 through 2025 by Geographic Region/Country - USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets
  • EXHIBIT 4: World 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Million Doses for USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets for Years 2021 & 2025
  • EXHIBIT 5: World Current & Future Analysis for COVID-19 Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets - Independent Analysis of Annual Doses in US$ Million for Years 2020 through 2025
  • EXHIBIT 6: World 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets for Years 2021 & 2025
VACCINES FOR KIDS
  • Kids: A Key to COVID-19 Controlling Efforts
  • US FDA Approves Pfizer-BioNTech Vaccine in Kids aged 5-11 Years, and 12 to 15 Years Age
  • Pfizer Approves Vaccine for Kids Aged 5-11 Years
  • Oxford University Halts AstraZeneca COVID-19 Vaccine Trial on Children over Perceived Safety Concerns
  • COVID-19 Vaccine Spikevax Approved for Children aged 12 to 17 in EU
REGIONAL MARKET PERSPECTIVE
  • THE UNITED STATES
  • Market Overview
  • Market Analytics
  • EXHIBIT 7: USA Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in Million Doses for the Years 2020 through 2025
  • EXHIBIT 8: USA Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in US$ Million for the Years 2020 through 2025
  • CANADA
  • Market Analytics
  • EXHIBIT 9: Canada Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in Million Doses for the Years 2020 through 2025
  • EXHIBIT 10: Canada Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in US$ Million for the Years 2020 through 2025
  • JAPAN
  • Market Analytics
  • EXHIBIT 11: Japanese Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in Million Doses for the Years 2020 through 2025
  • EXHIBIT 12: Japanese Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in US$ Million for the Years 2020 through 2025
  • CHINA
  • Market Analytics
  • EXHIBIT 13: Chinese Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in Million Doses for the Years 2020 through 2025
  • EXHIBIT 14: Chinese Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in US$ Million for the Years 2020 through 2025
  • EUROPE
  • EMA Approves Use of COVID-19 Vaccine of Pfizer for Children
  • Pfizer & Moderna Escalate Unit Price of COVID-19 Vaccines in Latest EU Contracts
  • Europe’s Horizon 2020
  • Market Analysis
  • UNITED KINGDOM
  • Vaccine Passport
  • UK Wins COVID-19 Vaccine Race with Approval of Pfizer-BioNTech Vaccine
  • The UK Approves AstraZeneca’s Vaccine
  • GERMANY
  • Germany Allows the Use of J&J Vaccine
  • SPAIN
  • Spain Prioritizes Frontline Healthcare Providers for Immunization Policy
  • NORWAY
  • Norway Bans AstraZeneca COVID-19 Vaccine
  • Market Analytics
  • EXHIBIT 15: European Current & Future Analysis for COVID-19 Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of European Markets - Independent Analysis of Annual Doses in Millions for Years 2020 through 2025
  • EXHIBIT 16: European 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Million Doses for France, Germany, Italy, UK, Spain, Russia, and Rest of European Markets for Years 2021 & 2025 Region 2021 2025
  • EXHIBIT 17: European Current & Future Analysis for COVID-19 Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of European Markets - Independent Analysis of Sales in US$ Million for Years 2020 through 2025
  • EXHIBIT 18: European 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of European Markets for Years 2021 & 2025
  • ASIA-PACIFIC
  • Market Analytics
  • EXHIBIT 19: Asia-Pacific Current & Future Analysis for COVID-19 Vaccines by Geographic Region - India, and Rest of Asia-Pacific Markets - Independent Analysis of Annual Doses in Millions for Years 2020 through 2025
  • EXHIBIT 20: Asia-Pacific 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Million Doses for India, and Rest of Asia-Pacific Markets for Years 2021 & 2025
  • EXHIBIT 21: Asia-Pacific Current & Future Analysis for COVID-19 Vaccines by Geographic Region - India, and Rest of Asia-Pacific Markets - Independent Analysis of Dollar Sales in US$ Million for Years 2020 through 2025
  • EXHIBIT 22: Asia-Pacific 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for India, and Rest of Asia-Pacific Markets for Years 2021 & 2025
  • THE MIDDLE EAST
  • Market Analytics
  • EXHIBIT 23: The Middle East Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in Million Doses for the Years 2020 through 2025
  • EXHIBIT 24: The Middle East Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in US$ Million for the Years 2020 through 2025
  • AFRICA
  • Market Analytics
  • EXHIBIT 25: African Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in Million Doses for the Years 2020 through 2025
  • EXHIBIT 26: African Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in US$ Million for the Years 2020 through 2025
  • LATIN AMERICA
  • Market Analytics
  • EXHIBIT 27: Latin American Current & Future Analysis for COVID-19 Vaccines by Geographic Region - Brazil, Mexico, and Rest of Latin American Markets - Independent Analysis of Annual Doses in Millions for Years 2020 through 2025
  • EXHIBIT 28: Latin American 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Million Doses for Brazil, Mexico, and Rest of Latin American Markets for Years 2021 & 2025
  • EXHIBIT 29: Latin American Current & Future Analysis for COVID-19 Vaccines by Geographic Region - Brazil, Mexico, and Rest of Latin American Markets - Independent Analysis of Dollar Sales in US$ Million for Years 2020 through 2025
  • EXHIBIT 30: Latin American 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for Brazil, Mexico, and Rest of Latin American Markets for Years 2021 & 2025
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
FOCUS ON THE FRONTRUNNERS
  • Moderna, Inc. (USA)
  • Pfizer Inc./BioNTech (US/Germany)
  • AstraZeneca/University of Oxford (The UK)
  • Johnson & Johnson (USA)
  • CanSino Biologics, Inc. (China)
  • China National Pharmaceutical Group Co., Ltd. (Sinopharm) (China)
  • Sinovac Biotech Ltd. (China)
  • Novavax, Inc. (USA)
  • Inovio Pharmaceuticals (USA)
  • Sanofi/GlaxoSmithKline (France/UK)
KEY VACCINE TECHNOLOGY PLATFORMSWORLD COVID-19 VACCINE BRANDSSELECT CORPORATE DEVELOPMENTS IN THE COVID-19 VACCINE MARKET: 2021III. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AstraZeneca PLC
  • Aurobindo Pharma Ltd.
  • Amyris, Inc.
  • AnGes, Inc.
  • Altimmune, Inc.
  • Arcturus Therapeutics, Inc.
  • ADImmune Corporation
  • AdaptVac
  • AJ Vaccines
  • Batavia Biosciences BV
  • ARTES Biotechnology GmbH
  • Baylor College of Medicine
  • baseclick GmbH
  • Barcelona Supercomputing Center
  • Akston Biosciences Corporation